GBNH - Cybin inks collaboration agreement with Greenbrook

Cybin ([[CLXPF]] +5.1%) has entered into an exclusive research and development collaboration agreement with TMS NeuroHealth Centers, a wholly-owned subsidiary of Greenbrook TMS ([[GBNH]] -0.0%).Pursuant to the agreement, Cybin and Greenbrook will work together to establish Mental Health Centers of Excellence for the purpose of facilitating research and development of innovative psychedelic compound-based therapeutics for patients suffering from depression.Specific projects to be pursued at the centers will look at: furthering clinical research of the psychedelic compounds in Cybin’s development pipeline; facilitating recruitment of clinical trial participants for upcoming trials, among others.Cybin had selected social anxiety disorder (“SAD”) and generalized anxiety disorder (“GAD”) as the initial target indications for its proprietary psychedelic molecule CYB004, last month.

For further details see:

Cybin inks collaboration agreement with Greenbrook